Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$776.38 USD

776.38
8,254,426

-29.68 (-3.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Kinjel Shah headshot

3 Stocks to Focus on as Demand for Obesity Drugs Booms

With the obesity market gaining popularity, analysts are expecting sales to increase. Pharma companies are rushing to enter the market

Kinjel Shah headshot

Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs

The European Commission approves AbbVie's (ABBV) Tepkinly (epcoritamab) for DLBCL. FDA approves Lilly's (LLY) Jardiance for chronic kidney disease.

Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies

Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC.

Eli Lilly (LLY) Stock Moves -0.41%: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $550.01, moving -0.41% from the previous trading session.

FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease

Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Sector ETF report for PJP

The Zacks Analyst Blog Highlights Eli Lilly, Toyota Motor, Accenture, The Walt Disney and CVS Health

Eli Lilly, Toyota Motor, Accenture, The Walt Disney and CVS Health are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Eli Lilly, Toyota Motor, Accenture & Others

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Toyota Motor Corporation (TM) and Accenture plc (ACN).

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Sector ETF report for IYH

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $574.96, marking a +0.64% move from the previous day.

Pfizer's (PFE) Alopecia Areata Drug Litfulo Receives EU Nod

Pfizer (PFE) gets marketing authorization in the EU for Litfulo to treat adults and adolescent patients aged 12 years and older with severe alopecia areata.

Should Invesco Large Cap Growth ETF (PWB) Be on Your Investing Radar?

Style Box ETF report for PWB

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Is Invesco Large Cap Growth ETF (PWB) a Strong ETF Right Now?

Smart Beta ETF report for PWB

Novo Nordisk (NVO) Announces Stock Split to Enhance Liquidity

Novo Nordisk (NVO) conducts a two-for-one stock split. While this is already in effect at the stock exchange in Denmark, the ADRs listed on the NYSE will be split in the same ratio by next week.

Nektar (NKTR) Up on Positive New Data From Eczema Study

Nektar (NKTR) gains on positive new data for its pipeline candidate, rezpegaldesleukin, evaluated from an early-stage study for treating atopic dermatitis.

Is Franklin U.S. Large Cap Multifactor Index ETF (FLQL) a Strong ETF Right Now?

Smart Beta ETF report for FLQL

Zacks Investment Ideas feature highlights: Novo Nordisk, Eli Lilly and AbbVie

Novo Nordisk, Eli Lilly and AbbVie have been highlighted in this Investment Ideas article.

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $598.88, moving -0.07% from the previous trading session.

Andrew Rocco headshot

"Blockbuster Status": 3 Bios to Buy and Hold

The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have broken through and are set up for long term growth.

Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study

Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line results in fourth-quarter 2023. The stock rises 7%.

Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?

Smart Beta ETF report for FTCS

NVS vs. LLY: Which Stock Is the Better Value Option?

NVS vs. LLY: Which Stock Is the Better Value Option?